Abstract
Single-crystal neutron diffraction data were collected at 20 K to a resolution of 1.05 Å on a crystal of the inverse formyl peptide receptor agonist cyclosporin H, CsH, (crystal form II, CsH-II) on the Laue diffractometer VIVALDI at the Institut Laue-Langevin (Grenoble). The solvent structure and hydrogen bonding network of CsH-II have been unambiguously determined by single-crystal neutron diffraction; the agreement factor R(F 2) is 13.5% for all 2726 reflections. All hydrogen atom positions, including methyl-group orientations, have been determined by crystallographic refinement. The neutron structure of cyclosporin provides unique and complementary insights into methyl orientation, hydrogen-bonding, and solvent interactions that are not available from X-ray analysis alone.
Index Abstract
CsH neutron structure showing the 7 waters and trace of the main chain N1---N11. All water hydrogens were determined experimentally. Thermal ellipsoids are plotted at 85% probability. Drawn with ORTEP-III/RASTER (Burnett and Johnson, Report ORNL-6895, 1996; Merritt and Bacon, Methods in Enzymology 277:505, 1997) as implemented in the program suite WinGX (Farrugia, Journal of Applied Crystallography 32(4):837, 1999) and generated by ORTEP-3 for Windows (Farrugia, Journal of Applied Crystallography 30(5):565, 1997). The main chain trace was drawn with RASMOL (Sayle, Glaxo research and development, 1994).
Similar content being viewed by others
References
Ko SY, Dalvit C (1992) Int J Pept Protein Res 40(5):380
Loosli HR, Kessler H, Oschkinat H, Weber HP, Petcher TJ, Widmer A (1985) Helvetica Chimica Acta 68(3):682
Altschuh D, Vix O, Rees B, Thierry JC (1992) Science 256(5053):92
Fesik SW, Gampe RT, Eaton HL, Gemmecker G, Olejniczak ET, Neri P, Holzman TF, Egan DA, Edalji R, Simmer R, Helfrich R, Hochlowski J, Jackson M (1991) Biochemistry 30(26):6574
Fesik SW, Neri P, Meadows R, Olejniczak ET, Gemmecker G (1992) J Am Chem Soc 114(8):3165
Kallen J, Mikol V, Taylor P, Walkinshaw MD (1998) J Mol Biol 283(2):435
Kessler H, Kock M, Wein T, Gehrke M (1990) Helvetica Chimica Acta 73(7):1818
Knott RB, Schefer J, Schoenborn BP (1990) Acta Crystallogr C Cryst Struct Commun 46:1528
Mikol V, Taylor P, Kallen J, Walkinshaw MD (1998) J Mol Biol 283(2):451
Weber C, Wider G, von Freyberg B, Traber R, Braun W, Widmer H, Wuthrich K (1991) Biochemistry 30(26):6563
Wuthrich K, Vonfreyberg B, Weber C, Wider G, Traber R, Widmer H, Braun W (1991) Science 254(5034):953
Potter B, Palmer RA, Withnall R, Jenkins TC, Chowdhry BZ (2003) Org Biomol Chem 1(9):1466
McIntyre GJ, Lemée-Cailleau M-H, Wilkinson C (2006) Phys B: Condens Matter 385–386:1055
Wilkinson C, Cowan JA, Myles DAA, Cipriani F, McIntyre GJ (2002) Neutron News 13:37
Campbell JW, Hao Q, Harding MM, Nguti ND, Wilkinson C (1998) J Appl Crystallogr 31(3):496
Wilkinson C, Khamis HW, Stansfield RFD, McIntyre GJ (1988) J Appl Crystallogr 21:471
Arzt S, Campbell JW, Harding MM, Hao Q, Helliwell JR (1999) J Appl Crystallogr 32(3):554
Evans PR (2006) Acta Crystallogr D Biol Cryst 62:72–82
Brunger AT (1992) Nature 355(6359):472
Brunger AT (1997) Methods Enzymol 277:366
Sheldrick GM (2008) Acta Crystallogr A 64(Pt 1):112
Sears VF (1992) Neutron News 3(3):26
Stegmann C, Seeliger D, Sheldrick G, de Groot B, Wahl M (2009) Angewandte Chemie (International ed. in English)
Sayle R (1994) Glaxo research and development. Greenfield, Middlesex, UK
Vaguine AA, Richelle J, Wodak SJ (1999) Acta Crystallogr D Biol Crystallogr 55(Pt 1):191
Burnett M, Johnson C (1996) Report ORNL-6895, Oak Ridge National Laboratory, Oak Ridge, TN, USA
Farrugia L (1997) J Appl Crystallogr 30(5):565
Merritt E, Bacon D (1997) Methods Enzymol 277:505
Farrugia L (1999) J Appl Crystallogr 32(4):837
Acknowledgments
We gratefully acknowledge the ILL for the provision of beamtime. We thank Professor Jon Cooper for his help and interest in the early stages of this study. We thank Ray Simpson for depicting the main chain trace shown in the Index Abstract figure. This research at Oak Ridge National Laboratory’s Center for Structural Molecular Biology (CSMB) was supported by the Office of Biological and Environmental Research, using facilities supported by the US Department of Energy, managed by UT-Battelle, LLC under contract No.DE-AC05-00OR22725. This research was supported in part by an appointment to the ORNL Postdoctoral Research Associates Program at the Oak Ridge National Laboratory, sponsored by the US Department of Energy and administered by the Oak Ridge Institute for Science and Education.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gardberg, A.S., Potter, B.S., Palmer, R.A. et al. The Neutron Structure of the Formyl Peptide Receptor Antagonist Cyclosporin H (CsH) Unambiguously Determines the Solvent and Hydrogen-Bonding Structure for Crystal Form II. J Chem Crystallogr 41, 470–480 (2011). https://doi.org/10.1007/s10870-010-9903-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10870-010-9903-7